Caplacizumab News
Caplacizumab currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Caplacizumab with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
- Evidence level: L2
- Predicted indications (20):
- primary release disorder of platelets (100.0%)
- pseudo-von Willebrand disease (100.0%)
- Glanzmann thrombasthenia (100.0%)
- Scott syndrome (100.0%)
- thrombotic thrombocytopenic purpura (100.0%)
- bleeding diathesis due to a collagen receptor defect (100.0%)
- hemorrhagic disorder due to a constitutional thrombocytopenia (100.0%)
- fetal and neonatal alloimmune thrombocytopenia (100.0%)
- hemophilia (100.0%)
- platelet-type bleeding disorder (100.0%)
- acquired coagulation factor deficiency (100.0%)
- thrombocytopenic purpura (100.0%)
- Ehlers-Danlos syndrome, fibronectinemic type (100.0%)
- inherited thrombophilia (100.0%)
- flood factor deficiency (100.0%)
- symptomatic form of hemophilia in female carriers (100.0%)
- congenital factor V deficiency (100.0%)
- hereditary thrombocytosis with transverse limb defect (100.0%)
- familial thrombomodulin anomalies (100.0%)
- methylcobalamin deficiency type cblG (100.0%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.